• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

CUDC-101 Provides Encouraging Results in Phase 1 Head and Neck Cancer


The drug targets multiple proteins that are overexpressed in head and neck cancer, the study published in Clinical Cancer Research says.

Head and neck cancer is among the few solid tumors whose incidence is increasing in the United States. and outcomes have been slow to improve. Results of a phase 1 trial of the drug CUDC-101 with radiation and chemotherapy were reported by the University of Colorado Cancer Center and 6 other US cancer centers in the journal Clinical Cancer Research.

CUDC-101, currently being developed by Curis, Inc, works by inhibiting two growth factors and an enzyme that effects DNA expression—EGFR, Her2 and HDAC—all of which are overexpressed in many cancers, including the target of this trial: the common type of especially aggressive head and neck cancer that is not caused by the human papilloma virus (HPV-) but rather by tobacco or alcohol.

Link to the complete report in ScienceDaily:


Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Chandler Cortina, MD, MS, FSSO, FACS | Image Credit: Froedtert & Medical College of Wisconsin
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
All rights reserved.